Screener
Halozyme Therapeutics HALO Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Financing activities | ||
| Repurchase of common stock | (332,729) | (303,489) |
| Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement | 4,865 | 1,202 |
| Net cash used in financing activities | (327,864) | (302,287) |
| Net increase (decrease) in cash and cash equivalents | 27,565 | (53,989) |
| Cash and cash equivalents at beginning of period | 136,421 | 115,850 |
| Cash and cash equivalents at end of period | $163,986 | $61,861 |
| Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's financing cash flow?
- Halozyme Therapeutics (HALO) reported financing cash flow of -$326.25M in Q2 2026.
- How has Halozyme Therapeutics's financing cash flow changed year-over-year?
- Halozyme Therapeutics's financing cash flow decreased by 9.1% year-over-year, from -$298.97M to -$326.25M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Halozyme Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude